Who is sponsoring NCT04549064?

NCT04549064 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What condition does NCT04549064 study?

NCT04549064 studies Pancreatic Cancer.

What drugs are being tested in NCT04549064?

Interventions: diagnosis of pancreatic cancer.

What is the status of NCT04549064?

NCT04549064 is currently UNKNOWN.

Last reviewed 2021-08-23 · How we verify

Biomarkers of Pancreatic Cancer and New Way to Detection

NCT04549064 UNKNOWN

Amphoteric regulatory protein (AREG), a member of epidermal growth factor (EGF) family, is expressed in many tumors.Our study confirmed that the expression of AREG in the serum of patients with pancreatic cancer is significantly higher than that of patients with benign pancreatic diseases and healthy people, which is expected to become a new early serum marker of pancreatic cancer. The serum concentration of AREG was detected by traditional ELISA and compared with CA-199, which was a conventional tumor marker of pancreatic cancer. Next, we compare the advantages of using sensor to detect AREG compared with ELISA.

Details

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Status	UNKNOWN
Enrolment	600
Start date	Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Pancreatic Cancer

Interventions

diagnosis of pancreatic cancer

Countries

China